Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
9 papers
Recent·Most cited
S. Basu, C. M. Reitmayer, S. Lumley, B. Atkinson, M. L. Schade-Weskott, S. Rooney, W. Larner, E. E. Montiel, R. Gutierrez-Lopez, E. Levitt, H. M. Munyanduki, A. M. E. Elrefaey, A. T. Clarke, S. Koit, E. Zusinaite, , L. Alphey
This paper describes a genetic system in Aedes aegypti mosquitoes that selectively eliminates ZIKV-infected individuals to reduce vectorial capacity.
bioRxiv · Feb 6, 2023 · PreprintBioengineering
A. Ianevski, R. Yao, R. M. Simonsen, V. Myhre, E. Ravlo, G. D. Kaynova, E. Zusinaite, J. M. White, Q. Pan, S. J. Polyak, V. Oksenych, M. P. Windisch, E. Lastauskiene, A. Vitkauskiene, A. Matukevicius, , D. E. Kainov
The paper develops scoring systems to predict novel broad-spectrum antivirals and combinations, aiming to improve preparedness for future viral outbreaks.
bioRxiv · Jan 15, 2022 · PreprintMicrobiology
A. Ianevski, R. Yao, E. Zusinaite, H. Lysvand, V. Oksenych, T. Tenson, M. Bjoras, D. E. Kainov
This study examines how active components of commonly prescribed medicines affect influenza A virus-host cell interactions both in silico and in vitro.
bioRxiv · Jul 11, 2021Pharmacology & Toxicology
A. Ianevski, R. Yo, H. Lysvand, G. Grodeland, N. Legrand, V. Oksenych, E. Zusinaite, T. Tenson, M. Bjoras, D. E. Kainov
This study combines nafamostat and interferon-alpha to suppress SARS-CoV-2 infection by targeting TMPRSS2 in vitro and in vivo.
bioRxiv · Jun 16, 2021Microbiology
A. Ianevski, R. Yao, E. Zusinaite, L. S. Lello, S. Wang, E. Jo, J. Yang, E. Ravlo, W. Wang, H. Lysvand, K. Loseth, V. Oksenych, T. Tenson, M. P. Windisch, M. Poranen, , D. E. Kainov
This study shows that IFNa-based combinations effectively inhibit SARS-CoV-2 infection in vitro and in vivo, with synergistic effects against other viruses.
bioRxiv · Jan 5, 2021 · PreprintMicrobiology
A. Ianevski, R. Yao, S. Biza, E. Zusinaite, A. Mannik, G. Kivi, A. Planken, K. Kurg, E.-M. Tombak, M. Ustav, N. Shtaida, E. Kulesskiy, E. Jo, J. Yang, H. Lysvand, , D. E. Kainov
This study identifies novel synergistic antiviral drug combinations effective against SARS-CoV-2, echovirus 1, HCV, and HIV-1 in vitro and provides an online resource for their developmental status.
bioRxiv · Sep 17, 2020 · PreprintMicrobiology
A. Ianevski, R. Yao, M. H. Fenstad, S. Biza, E. Zusinaite, H. Lysvand, K. Loeseth, V. M. Lamndsem, J. F. Malmring, V. Oksenych, S. E. Erlandsen, P. A. Aas, L. Hagen, C. H. Pettersen, J. E. Afset, , D. E. Kainov
The paper identifies potent convalescent sera and broad-spectrum antivirals effective against SARS-CoV-2 using a neutralization assay and cell culture screening.
bioRxiv · May 12, 2020Microbiology
A. Ianevski, E. Kulesskiy, K. Krpina, G. Lou, Y. Aman, A. Bugai, K. Aasumets, Y. Akimov, D. Bulanova, K. Gildemann, A. F. Arutyunyan, O. Y. Susova, A. L. Zhuze, P. Ji, W. Wang, , D. E. Kainov
This study shows that Bcl-xL-specific inhibitors, when combined with DNA-damaging agents or physical insults, trigger apoptosis in various cell types and C. elegans by releasing Bad and Bax from Bcl-xL.
bioRxiv · Jan 13, 2020Cancer Biology
K. Bosl, A. Ianevski, T. T. Than, P. I. Andersen, S. Kuivanen, M. Teppor, E. Zusinaite, U. Dumpis, A. Vitkauskiene, R. J. Cox, H. Kallio-Kokko, A. Bergqvist, T. Tenson, V. Oksenych, M. Bjoras, , R. K. Kandasamy
This study identifies critical host-virus interaction nodes through network analysis and drug re-purposing, revealing key targets for antiviral therapies.
bioRxiv · Feb 13, 2019 · PreprintImmunology